TY - BOOK ID - 14296192 TI - History of research on tumor angiogenesis PY - 2009 SN - 1402095597 9048181569 9786611954796 1281954799 1402095635 PB - Dordrecht : Springer Netherlands, DB - UniCat KW - Neovascularization inhibitors. KW - Neovascularization. KW - Tumors -- Blood-vessels -- Growth. KW - Tumors. KW - Tumors KW - Neovascularization KW - Neovascularization inhibitors KW - Cardiovascular Physiological Processes KW - Growth Inhibitors KW - Metaplasia KW - Metabolic Phenomena KW - Antineoplastic Agents KW - Growth Substances KW - Diseases KW - Science KW - Physiological Effects of Drugs KW - Pathologic Processes KW - Therapeutic Uses KW - Natural Science Disciplines KW - Cardiovascular Physiological Phenomena KW - Phenomena and Processes KW - Pharmacologic Actions KW - Circulatory and Respiratory Physiological Phenomena KW - Disciplines and Occupations KW - Pathological Conditions, Signs and Symptoms KW - Chemical Actions and Uses KW - Chemicals and Drugs KW - Neoplasms KW - Angiogenesis Inhibitors KW - Angiogenesis Modulating Agents KW - Neovascularization, Physiologic KW - Neovascularization, Pathologic KW - Research KW - Metabolism KW - Medicine KW - Health & Biological Sciences KW - Oncology KW - Blood-vessels KW - Growth KW - Blood-vessels. KW - Treatment. KW - Cancer KW - Tumours KW - Medicine. KW - History. KW - Cancer research. KW - Oncology. KW - Pathology. KW - Cell biology. KW - Biomedicine. KW - Cancer Research. KW - History of Science. KW - Cell Biology. KW - Pathology KW - Cysts (Pathology) KW - Oncology . KW - Cytology. KW - Cell biology KW - Cellular biology KW - Biology KW - Cells KW - Cytologists KW - Disease (Pathology) KW - Medical sciences KW - Medicine, Preventive KW - Annals KW - Auxiliary sciences of history KW - Cancer research UR - https://www.unicat.be/uniCat?func=search&query=sysid:14296192 AB - In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. ER -